Natural killer cell hyporesponsiveness and impaired development in a CD247-deficient patient.

We thank Niek P. van Til, Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands, for providing the wild-type gcPRO plasmid. Anita Chandra, MRCP, FRCPath, PhD* Fang Zhang, PhD* Kimberly C. Gilmour, FRCPath, PhD David Webster, FRCPath Vincent Plagnol, PhD Dinakantha S. Kumararatne, FRCPath, DPhil Siobhan O. Burns, MB, PhD, MRCPI(Paeds) Sergey Nejentsev, MD, PhD Adrian J. Thrasher, MRCP, PhD From the Department of Clinical Biochemistry and Immunology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; Lymphocyte Signalling & Development, Babraham Institute, Cambridge, United Kingdom; Molecular and Cellular Immunology, Institute of Child Health, University College London, London, United Kingdom; the Department of Immunology, Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom; University College London Institute of Immunity and Transplantation, London, United Kingdom; the Department of Medicine, University of Cambridge, Cambridge, United Kingdom; Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom; University College London Genetics Institute, University College London, London, United Kingdom; and the Department of Immunology, Royal Free London NHS Foundation Trust, London, United Kingdom. E-mail: anita.chandra@ doctors.org.uk. *These authors contributed equally to this work. S.N. is a Wellcome Trust Senior Research Fellow in Basic Biomedical Science (095198/ Z/10/Z). S.N. is also supported by the European Research Council Starting grant 260477 and the EU FP7 collaborative grant 261441 (PEVNET project) and a National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre. F.Z. is funded by an EU FP7 grant: CELL-PID—Advanced Cell-based therapies for the treatment of primary immunodeficiencies (reference no. FP7-261387). A.C. has a Wellcome Trust Postdoctoral Training Fellowship for Clinicians (103413/Z/13/Z). A.J.T. is a Wellcome Trust Principal Fellow. Disclosure of potential conflict of interest: A. Chandra and D. S. Kumararatne received travel support from Shire. S. O. Burns received travel support from Immunodeficiency Canada, CSL Behring. and Baxalta US. The rest of the authors declare that have no relevant conflicts of interest.